Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Retained Earnings (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Retained Earnings for 8 consecutive years, with -$628.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 19.56% to -$628.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$628.8 million, a 19.56% decrease, with the full-year FY2025 number at -$605.7 million, changed N/A from a year prior.
  • Retained Earnings was -$628.8 million for Q4 2025 at Outlook Therapeutics, down from -$605.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$525.9 million in Q4 2024 to a low of -$628.8 million in Q4 2025.